GlaxoSmithKline PLC (GSK): Price and Financial Metrics
GlaxoSmithKline PLC (GSK)
Today's Latest Price: $37.40 USD
Updated Dec 2 4:00pm
Add GSK to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
GSK Stock Summary
- With a market capitalization of $100,986,997,854, Glaxosmithkline Plc has a greater market value than 97.96% of US stocks.
- GSK's went public 34.42 years ago, making it older than 92.48% of listed US stocks we're tracking.
- In terms of volatility of its share price, GSK is more volatile than just 2.33% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to Glaxosmithkline Plc, a group of peers worth examining would be IBM, CAT, SYK, AXP, and INTU.
- Visit GSK's SEC page to see the company's official filings. To visit the company's web site, go to www.gsk.com.
GSK Stock Price Chart Interactive Chart >
GSK Price/Volume Stats
| Current price | $37.40 | 52-week high | $48.25 |
| Prev. close | $37.52 | 52-week low | $31.43 |
| Day low | $37.28 | Volume | 4,170,329 |
| Day high | $37.64 | Avg. volume | 4,057,596 |
| 50-day MA | $36.75 | Dividend yield | 5.2% |
| 200-day MA | $39.43 | Market Cap | 93.82B |
GlaxoSmithKline PLC (GSK) Company Bio
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The companys wellness products include Panadol and Panadol Cold & Flu, ENO and Tums - antacids, and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate - treatment of nicotine withdrawal, Sensodyne - to ttreat and prevent dental sensitivity, Polident, Poligrip, and Corega to enhance comfort of fitted denture, and Aquafresh for the prevention of gum disease and bad breath. The company was founded in 1935 and is based, the United Kingdom.
GSK Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $37.40 | $21.55 | -42% |
Below please find a table outlining a discounted cash flow forecast for GSK, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Glaxosmithkline Plc ranked in the 36th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for GSK, they are:
- The company has produced more trailing twelve month cash flow than 94.58% of its sector Healthcare.
- Glaxosmithkline Plc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than only 22.84% of tickers in our DCF set.
- GSK's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than only 22.84% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -43% |
| 1% | -42% |
| 2% | -42% |
| 3% | -41% |
| 4% | -41% |
| 5% | -40% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as GSK, try TMO, ITGR, OFIX, PKI, and HOLX.
Loading social stream, please wait...